

William Jacot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357453/publications.pdf>

Version: 2024-02-01

79
papers

2,573
citations

218677

26
h-index

233421

45
g-index

85
all docs

85
docs citations

85
times ranked

3861
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequent expression of PD-1 on circulating breast cancer cells. <i>Molecular Oncology</i> , 2015, 9, 1773-1782.	4.6	303
2	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
3	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
4	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. <i>European Journal of Cancer</i> , 2020, 129, 60-70.	2.8	103
5	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	2.5	101
6	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	7.1	92
7	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
8	Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. <i>Cancers</i> , 2020, 12, 958.	3.7	77
9	Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the APAD1 randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 737.	2.6	73
10	Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29.		63
11	Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. <i>Cancers</i> , 2021, 13, 6059.	3.7	60
12	Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. <i>Breast Cancer Research</i> , 2011, 13, R15.	5.0	56
13	Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. <i>Molecular Oncology</i> , 2014, 8, 431-443.	4.6	48
14	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018, 119, 76-79.	6.4	48
15	BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. <i>BMC Cancer</i> , 2013, 13, 523.	2.6	44
16	Iron homeostasis and anemia markers in early breast cancer. <i>Clinica Chimica Acta</i> , 2014, 434, 34-40.	1.1	42
17	Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 709-717.	2.5	38
18	Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1503-1512.	3.2	38

#	ARTICLE	IF	CITATIONS
19	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. <i>Breast Cancer Research</i> , 2011, 13, R133.	5.0	37
20	Multicenter evaluation of breast cancer patients'™ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	6.4	37
21	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	3.2	33
22	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 115.	5.2	33
23	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	2.2	31
24	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	3.7	31
25	Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. <i>European Journal of Cancer</i> , 2020, 125, 22-30.	2.8	31
26	Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. <i>BMC Cancer</i> , 2015, 15, 659.	2.6	30
27	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 58-73.	4.4	30
28	Diversity of Tumor-Infiltrating, $\gamma\delta$ T-Cell Abundance in Solid Cancers. <i>Cells</i> , 2020, 9, 1537.	4.1	30
29	Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. <i>International Journal of Cancer</i> , 2019, 145, 3359-3369.	5.1	29
30	Identification of a regulatory $\gamma\delta$ 1 gamma delta T cell subpopulation expressing CD73 in human breast cancer. <i>Journal of Leukocyte Biology</i> , 2020, 107, 1057-1067.	3.3	27
31	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	3.7	27
32	A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. <i>Theranostics</i> , 2021, 11, 6173-6192.	10.0	27
33	Prognostic factors of brain metastases from breast cancer: Impact of targeted therapies. <i>Breast</i> , 2013, 22, 993-998.	2.2	25
34	Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. <i>International Journal of Cancer</i> , 2016, 139, 2299-2311.	5.1	23
35	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	2.9	22
36	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 2328.	3.7	20

#	ARTICLE	IF	CITATIONS
37	The prognostic value of the τ protein serum level in metastatic breast cancer patients and its correlation with brain metastases. <i>BMC Cancer</i> , 2019, 19, 110.	2.6	20
38	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.	2.6	19
39	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	2.9	19
40	Prognostic Value of CXCR2 in Breast Cancer. <i>Cancers</i> , 2020, 12, 2076.	3.7	19
41	Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. <i>BMC Cancer</i> , 2013, 13, 70.	2.6	17
42	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667.	2.5	17
43	High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker. <i>Frontiers in Oncology</i> , 2019, 9, 1141.	2.8	17
44	Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 2666.	3.7	17
45	Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?. <i>Future Oncology</i> , 2015, 11, 557-559.	2.4	15
46	Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 770.	2.6	15
47	Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial. <i>Nutrients</i> , 2020, 12, 3081.	4.1	15
48	Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. <i>Cancers</i> , 2020, 12, 1244.	3.7	15
49	Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. <i>BMC Cancer</i> , 2010, 10, 257.	2.6	14
50	Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and 1833-41.	2.3	14
51	Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2013, 36, 531-543.	1.8	13
52	Clinicopathological Correlates of γ T Cell Infiltration in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 765.	3.7	13
53	Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 705-713.	2.5	12
54	Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2 α ⁻ pN0 early breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 611-621.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020, 23, 193-202.	7.2	11
56	In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired resistance derive from quiescent residual cancer cells that overexpress <i>CRYAB</i> , <i>CEACAM6</i> and <i>SOX2</i> . <i>Journal of Pathology</i> , 2022, 257, 367-378.	4.5	11
57	Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. <i>Clinical and Translational Medicine</i> , 2014, 3, 31.	4.0	10
58	Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 144-149.	2.4	10
59	Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammoplasty Technique. <i>Annals of Surgical Oncology</i> , 2015, 22, 486-494.	1.5	9
60	Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort. <i>International Journal of Cancer</i> , 2022, 151, 1355-1366.	5.1	9
61	Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?. <i>Cancer Management and Research</i> , 2019, Volume 11, 10353-10373.	1.9	8
62	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	3.3	8
63	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1605-1618.	5.1	8
64	Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 188, 113438.	2.8	7
65	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. <i>Quality of Life Research</i> , 2021, 30, 91-103.	3.1	7
66	Alpelisib for the treatment of <i>PIK3CA</i> -mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 667-675.	1.8	7
67	Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. <i>International Journal of Cancer</i> , 2019, 145, 1299-1311.	5.1	6
68	Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures. <i>Supportive Care in Cancer</i> , 2022, 30, 3633-3641.	2.2	6
69	Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database. <i>Journal of Medical Economics</i> , 2017, 20, 1261-1267.	2.1	5
70	A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Nutrients</i> , 2021, 13, 4429.	4.1	5
71	Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. <i>Pharmaceutics</i> , 2022, 14, 841.	4.5	4
72	Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program. <i>Breast</i> , 2021, 56, 18-25.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer. <i>BMC Cancer</i> , 2021, 21, 815.	2.6	2
74	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
75	Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer. <i>Lancet Oncology</i> , The, 2022, 23, 557-558.	10.7	1
76	CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017, 19, vi45-vi45.	1.2	0
77	Exploring Sensitivity to Replicative Stress in BRCA-Deficient Triple Negative Breast Cancer. <i>Medical Sciences Forum</i> , 2021, 3, .	0.5	0
78	Abstract P2-01-12: Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study. <i>Cancer Research</i> , 2022, 82, P2-01-12-P2-01-12.	0.9	0
79	Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	0